|
Sunday, June 5, 2022, Chicago, Illinois, 6:45 AM – 7:45 AM Central Time (7:45 AM – 8:45 AM Eastern Time)
Breakfast with the Investigators: Ovarian CancerA CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, IL 60605 Hotel Phone: (312) 922-4400 Program Schedule — Central Time 6:15 AM – 6:45 AM — Registration and Breakfast 6:45 AM – 7:45 AM — Educational Meeting Meeting Room Grand Ballroom (Level 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Antonio González-Martín, MD, PhD Co-Director, Oncology Department Cancer Center Director, Clínica Universidad de Navarra Madrid, Spain Joyce F Liu, MD, MPH Associate Chief and Director of Clinical Research Division of Gynecologic Oncology Dana-Farber Cancer Institute Boston, Massachusetts Kathleen N Moore, MD, MS Virginia Kerley Cade Chair in Developmental Therapeutics Associate Director for Clinical Research Director, Early Phase Drug Development Stephenson Cancer Center at the University of Oklahoma HSC Professor, Section of Gynecologic Oncology Associate Program Director, Gynecologic Oncology Fellowship University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma Moderator Neil Love, MD Research To Practice Miami, Florida This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Mersana Therapeutics Inc, and Novocure Inc.
Program Schedule — Central Time 6:15 AM – 6:45 AM — Registration and Breakfast 6:45 AM – 7:45 AM — Educational Meeting MODULE 1: First-Line Treatment Decision-Making for Patients with Advanced Ovarian Cancer (OC)
MODULE 2: Management of Relapsed OC; Future Directions with PARP Inhibitor Therapy for Newly Diagnosed and Recurrent Disease
MODULE 3: Other Novel Agents and Strategies Under Investigation for Advanced OC
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr González-Martín — Advisory Committee and Consulting Agreements: Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genmab, GlaxoSmithKline, ImmunoGen Inc, MacroGenics Inc, Merck, Merck Sharp & Dohme LLC, Mersana Therapeutics Inc, Novartis, Oncoinvent, Pfizer Inc, PharmaMar, Roche Laboratories Inc, SOTIO LLC, Sutro Biopharma; Contracted Research: GlaxoSmithKline, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme LLC, PharmaMar, Roche Laboratories Inc. Dr Liu — Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Epsila Bio, Genentech, a member of the Roche Group, GlaxoSmithKline, Regeneron Pharmaceuticals Inc; Trial Support to Institution for Study Conduct: 2X Oncology, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, GlaxoSmithKline, Regeneron Pharmaceuticals Inc, Surface Oncology, Tesaro, A GSK Company, Vigeo Therapeutics, Zentalis Pharmaceuticals. Dr Moore — Advisory Committee: Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Eisai Inc, Elevar Therapeutics, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, IMXmed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Lilly, Merck, PTC Therapeutics; Data and Safety Monitoring Board/Committee: SQZ Biotech.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose. SupportersThis activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Merck, Mersana Therapeutics Inc, and Novocure Inc. Hilton Chicago Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:15 AM Central Time on Sunday, June 5. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. Please note, onsite registration does not guarantee meal service which will be based on availability. Registration for live webcast
Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. Registration for Webcast »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation. |